Colby Chiang
Washington University in St. Louis
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Colby Chiang.
Genome Biology | 2014
Ryan M. Layer; Colby Chiang; Aaron R. Quinlan; Ira M. Hall
Comprehensive discovery of structural variation (SV) from whole genome sequencing data requires multiple detection signals including read-pair, split-read, read-depth and prior knowledge. Owing to technical challenges, extant SV discovery algorithms either use one signal in isolation, or at best use two sequentially. We present LUMPY, a novel SV discovery framework that naturally integrates multiple SV signals jointly across multiple samples. We show that LUMPY yields improved sensitivity, especially when SV signal is reduced owing to either low coverage data or low intra-sample variant allele frequency. We also report a set of 4,564 validated breakpoints from the NA12878 human genome. https://github.com/arq5x/lumpy-sv.
American Journal of Human Genetics | 2011
Michael E. Talkowski; Sureni V Mullegama; Jill A. Rosenfeld; Bregje W.M. van Bon; Yiping Shen; Elena A. Repnikova; Julie M. Gastier-Foster; Devon Lamb Thrush; Sekar Kathiresan; Douglas M. Ruderfer; Colby Chiang; Carrie Hanscom; Carl Ernst; Amelia M. Lindgren; Cynthia C. Morton; Yu An; Caroline Astbury; Louise Brueton; Klaske D. Lichtenbelt; Lesley C. Adès; Marco Fichera; Corrado Romano; Jeffrey W. Innis; Charles A. Williams; Dennis Bartholomew; Margot I. Van Allen; Aditi Shah Parikh; Lilei Zhang; Bai-Lin Wu; Robert E. Pyatt
Persons with neurodevelopmental disorders or autism spectrum disorder (ASD) often harbor chromosomal microdeletions, yet the individual genetic contributors within these regions have not been systematically evaluated. We established a consortium of clinical diagnostic and research laboratories to accumulate a large cohort with genetic alterations of chromosomal region 2q23.1 and acquired 65 subjects with microdeletion or translocation. We sequenced translocation breakpoints; aligned microdeletions to determine the critical region; assessed effects on mRNA expression; and examined medical records, photos, and clinical evaluations. We identified a single gene, methyl-CpG-binding domain 5 (MBD5), as the only locus that defined the critical region. Partial or complete deletion of MBD5 was associated with haploinsufficiency of mRNA expression, intellectual disability, epilepsy, and autistic features. Fourteen alterations, including partial deletions of noncoding regions not typically captured or considered pathogenic by current diagnostic screening, disrupted MBD5 alone. Expression profiles and clinical characteristics were largely indistinguishable between MBD5-specific alteration and deletion of the entire 2q23.1 interval. No copy-number alterations of MBD5 were observed in 7878 controls, suggesting MBD5 alterations are highly penetrant. We surveyed MBD5 coding variations among 747 ASD subjects compared to 2043 non-ASD subjects analyzed by whole-exome sequencing and detected an association with a highly conserved methyl-CpG-binding domain missense variant, p.79Gly>Glu (c.236G>A) (p = 0.012). These results suggest that genetic alterations of MBD5 cause features of 2q23.1 microdeletion syndrome and that this epigenetic regulator significantly contributes to ASD risk, warranting further consideration in research and clinical diagnostic screening and highlighting the importance of chromatin remodeling in the etiology of these complex disorders.
American Journal of Human Genetics | 2011
Michael E. Talkowski; Carl Ernst; Adrian Heilbut; Colby Chiang; Carrie Hanscom; Amelia M. Lindgren; Andrew Kirby; Shangtao Liu; Bhavana Muddukrishna; Toshiro K. Ohsumi; Yiping Shen; Mark L. Borowsky; Mark J. Daly; Cynthia C. Morton; James F. Gusella
The contribution of balanced chromosomal rearrangements to complex disorders remains unclear because they are not detected routinely by genome-wide microarrays and clinical localization is imprecise. Failure to consider these events bypasses a potentially powerful complement to single nucleotide polymorphism and copy-number association approaches to complex disorders, where much of the heritability remains unexplained. To capitalize on this genetic resource, we have applied optimized sequencing and analysis strategies to test whether these potentially high-impact variants can be mapped at reasonable cost and throughput. By using a whole-genome multiplexing strategy, rearrangement breakpoints could be delineated at a fraction of the cost of standard sequencing. For rearrangements already mapped regionally by karyotyping and fluorescence in situ hybridization, a targeted approach enabled capture and sequencing of multiple breakpoints simultaneously. Importantly, this strategy permitted capture and unique alignment of up to 97% of repeat-masked sequences in the targeted regions. Genome-wide analyses estimate that only 3.7% of bases should be routinely omitted from genomic DNA capture experiments. Illustrating the power of these approaches, the rearrangement breakpoints were rapidly defined to base pair resolution and revealed unexpected sequence complexity, such as co-occurrence of inversion and translocation as an underlying feature of karyotypically balanced alterations. These findings have implications ranging from genome annotation to de novo assemblies and could enable sequencing screens for structural variations at a cost comparable to that of microarrays in standard clinical practice.
Nature Methods | 2015
Colby Chiang; Ryan M. Layer; Gregory G. Faust; Michael R. Lindberg; David B Rose; Erik Garrison; Gabor T. Marth; Aaron R. Quinlan; Ira M. Hall
SpeedSeq is an open-source genome analysis platform that accomplishes alignment, variant detection and functional annotation of a 50× human genome in 13 h on a low-cost server and alleviates a bioinformatics bottleneck that typically demands weeks of computation with extensive hands-on expert involvement. SpeedSeq offers performance competitive with or superior to current methods for detecting germline and somatic single-nucleotide variants, structural variants, insertions and deletions, and it includes novel functionality for streamlined interpretation.
American Journal of Human Genetics | 2012
Michael E. Talkowski; Gilles Maussion; Liam Crapper; Jill A. Rosenfeld; Ian Blumenthal; Carrie Hanscom; Colby Chiang; Amelia M. Lindgren; Shahrin Pereira; Douglas M. Ruderfer; Alpha B. Diallo; Juan Pablo Lopez; Gustavo Turecki; Elizabeth Suchi Chen; Carolina Oliveira Gigek; David J. Harris; Va Lip; Yu An; Marta Biagioli; Marcy E. MacDonald; Mike Lin; Stephen J. Haggarty; Pamela Sklar; Shaun Purcell; Manolis Kellis; Stuart Schwartz; Lisa G. Shaffer; Marvin R. Natowicz; Yiping Shen; Cynthia C. Morton
Large intergenic noncoding (linc) RNAs represent a newly described class of ribonucleic acid whose importance in human disease remains undefined. We identified a severely developmentally delayed 16-year-old female with karyotype 46,XX,t(2;11)(p25.1;p15.1)dn in the absence of clinically significant copy number variants (CNVs). DNA capture followed by next-generation sequencing of the translocation breakpoints revealed disruption of a single noncoding gene on chromosome 2, LINC00299, whose RNA product is expressed in all tissues measured, but most abundantly in brain. Among a series of additional, unrelated subjects referred for clinical diagnostic testing who showed CNV affecting this locus, we identified four with exon-crossing deletions in association with neurodevelopmental abnormalities. No disruption of the LINC00299 coding sequence was seen in almost 14,000 control subjects. Together, these subjects with disruption of LINC00299 implicate this particular noncoding RNA in brain development and raise the possibility that, as a class, abnormalities of lincRNAs may play a significant role in human developmental disorders.
Nature | 2015
Ronen Durst; Kimberly Sauls; David S. Peal; Annemarieke deVlaming; Katelynn Toomer; Maire Leyne; Monica Salani; Michael E. Talkowski; Harrison Brand; Maelle Perrocheau; Charles Simpson; Christopher Jett; Matthew R. Stone; Florie A. Charles; Colby Chiang; Stacey N. Lynch; Nabila Bouatia-Naji; Francesca N. Delling; Lisa A. Freed; Christophe Tribouilloy; Thierry Le Tourneau; Hervé Lemarec; Leticia Fernandez-Friera; Jorge Solis; Daniel Trujillano; Stephan Ossowski; Xavier Estivill; Christian Dina; Patrick Bruneval; Adrian H. Chester
Mitral valve prolapse (MVP) is a common cardiac valve disease that affects nearly 1 in 40 individuals. It can manifest as mitral regurgitation and is the leading indication for mitral valve surgery. Despite a clear heritable component, the genetic aetiology leading to non-syndromic MVP has remained elusive. Four affected individuals from a large multigenerational family segregating non-syndromic MVP underwent capture sequencing of the linked interval on chromosome 11. We report a missense mutation in the DCHS1 gene, the human homologue of the Drosophila cell polarity gene dachsous (ds), that segregates with MVP in the family. Morpholino knockdown of the zebrafish homologue dachsous1b resulted in a cardiac atrioventricular canal defect that could be rescued by wild-type human DCHS1, but not by DCHS1 messenger RNA with the familial mutation. Further genetic studies identified two additional families in which a second deleterious DCHS1 mutation segregates with MVP. Both DCHS1 mutations reduce protein stability as demonstrated in zebrafish, cultured cells and, notably, in mitral valve interstitial cells (MVICs) obtained during mitral valve repair surgery of a proband. Dchs1+/− mice had prolapse of thickened mitral leaflets, which could be traced back to developmental errors in valve morphogenesis. DCHS1 deficiency in MVP patient MVICs, as well as in Dchs1+/− mouse MVICs, result in altered migration and cellular patterning, supporting these processes as aetiological underpinnings for the disease. Understanding the role of DCHS1 in mitral valve development and MVP pathogenesis holds potential for therapeutic insights for this very common disease.
Human Genetics | 2013
Amelia M. Lindgren; Tatiana Hoyos; Michael E. Talkowski; Carrie Hanscom; Ian Blumenthal; Colby Chiang; Carl Ernst; Shahrin Pereira; Zehra Ordulu; Carol L. Clericuzio; Joanne M. Drautz; Jill A. Rosenfeld; Lisa G. Shaffer; Lea Velsher; Tania Pynn; Joris Vermeesch; David J. Harris; James F. Gusella; Eric C. Liao; Cynthia C. Morton
We describe a female subject (DGAP100) with a 46,X,t(X;5)(p11.3;q35.3)inv(5)(q35.3q35.1)dn, severe psychomotor retardation with hypotonia, global postnatal growth restriction, microcephaly, globally reduced cerebral volume, seizures, facial dysmorphia and cleft palate. Fluorescence in situ hybridization and whole-genome sequencing demonstrated that the X chromosome breakpoint disrupts KDM6A in the second intron. No genes were directly disrupted on chromosome 5. KDM6A is a histone 3 lysine 27 demethylase and a histone 3 lysine 4 methyltransferase. Expression of KDM6A is significantly reduced in DGAP100 lymphoblastoid cells compared to control samples. We identified nine additional cases with neurodevelopmental delay and various other features consistent with the DGAP100 phenotype with copy number variation encompassing KDM6A from microarray databases. We evaluated haploinsufficiency of kdm6a in a zebrafish model. kdm6a is expressed in the pharyngeal arches and ethmoid plate of the developing zebrafish, while a kdm6a morpholino knockdown exhibited craniofacial defects. We conclude KDM6A dosage regulation is associated with severe and diverse structural defects and developmental abnormalities.
Genome Research | 2015
Wesley C. Warren; Anna J. Jasinska; Raquel García-Pérez; Hannes Svardal; Chad Tomlinson; Mariano Rocchi; Nicoletta Archidiacono; Patrick Minx; Michael J. Montague; Kim Kyung; LaDeana W. Hillier; Milinn Kremitzki; Tina Graves; Colby Chiang; Jennifer F. Hughes; Nam Tran; Yu Huang; Vasily Ramensky; Oi Wa Choi; Yoon Jung; Christopher A. Schmitt; Nikoleta Juretic; Jessica Wasserscheid; Trudy R. Turner; Roger W. Wiseman; Jennifer J. Tuscher; Julie A. Karl; Jörn E. Schmitz; Roland Zahn; David H. O'Connor
We describe a genome reference of the African green monkey or vervet (Chlorocebus aethiops). This member of the Old World monkey (OWM) superfamily is uniquely valuable for genetic investigations of simian immunodeficiency virus (SIV), for which it is the most abundant natural host species, and of a wide range of health-related phenotypes assessed in Caribbean vervets (C. a. sabaeus), whose numbers have expanded dramatically since Europeans introduced small numbers of their ancestors from West Africa during the colonial era. We use the reference to characterize the genomic relationship between vervets and other primates, the intra-generic phylogeny of vervet subspecies, and genome-wide structural variations of a pedigreed C. a. sabaeus population. Through comparative analyses with human and rhesus macaque, we characterize at high resolution the unique chromosomal fission events that differentiate the vervets and their close relatives from most other catarrhine primates, in whom karyotype is highly conserved. We also provide a summary of transposable elements and contrast these with the rhesus macaque and human. Analysis of sequenced genomes representing each of the main vervet subspecies supports previously hypothesized relationships between these populations, which range across most of sub-Saharan Africa, while uncovering high levels of genetic diversity within each. Sequence-based analyses of major histocompatibility complex (MHC) polymorphisms reveal extremely low diversity in Caribbean C. a. sabaeus vervets, compared to vervets from putatively ancestral West African regions. In the C. a. sabaeus research population, we discover the first structural variations that are, in some cases, predicted to have a deleterious effect; future studies will determine the phenotypic impact of these variations.
Nature Genetics | 2017
Natalie D. Shaw; Harrison Brand; Zachary A. Kupchinsky; Hemant Bengani; Lacey Plummer; Takako I. Jones; Serkan Erdin; Kathleen A. Williamson; Joe Rainger; Alexei Stortchevoi; Kaitlin E. Samocha; Benjamin Currall; Donncha S. Dunican; Ryan L. Collins; Jason R. Willer; Angela Lek; Monkol Lek; Malik Nassan; Shahrin Pereira; Tammy Kammin; Diane Lucente; Alexandra Silva; Catarina M. Seabra; Colby Chiang; Yu An; Morad Ansari; Jacqueline K. Rainger; Shelagh Joss; Jill Clayton Smith; Margaret F. Lippincott
Arhinia, or absence of the nose, is a rare malformation of unknown etiology that is often accompanied by ocular and reproductive defects. Sequencing of 40 people with arhinia revealed that 84% of probands harbor a missense mutation localized to a constrained region of SMCHD1 encompassing the ATPase domain. SMCHD1 mutations cause facioscapulohumeral muscular dystrophy type 2 (FSHD2) via a trans-acting loss-of-function epigenetic mechanism. We discovered shared mutations and comparable DNA hypomethylation patterning between these distinct disorders. CRISPR/Cas9-mediated alteration of smchd1 in zebrafish yielded arhinia-relevant phenotypes. Transcriptome and protein analyses in arhinia probands and controls showed no differences in SMCHD1 mRNA or protein abundance but revealed regulatory changes in genes and pathways associated with craniofacial patterning. Mutations in SMCHD1 thus contribute to distinct phenotypic spectra, from craniofacial malformation and reproductive disorders to muscular dystrophy, which we speculate to be consistent with oligogenic mechanisms resulting in pleiotropic outcomes.
Nature | 2017
Xin Li; Yungil Kim; Emily K. Tsang; Joe R. Davis; Farhan N. Damani; Colby Chiang; Gaelen T. Hess; Zachary Zappala; Benjamin J. Strober; Alexandra J. Scott; Amy Li; Andrea Ganna; Michael C. Bassik; Jason D. Merker; Ira M. Hall; Alexis Battle; Stephen B. Montgomery
Rare genetic variants are abundant in humans and are expected to contribute to individual disease risk. While genetic association studies have successfully identified common genetic variants associated with susceptibility, these studies are not practical for identifying rare variants. Efforts to distinguish pathogenic variants from benign rare variants have leveraged the genetic code to identify deleterious protein-coding alleles, but no analogous code exists for non-coding variants. Therefore, ascertaining which rare variants have phenotypic effects remains a major challenge. Rare non-coding variants have been associated with extreme gene expression in studies using single tissues, but their effects across tissues are unknown. Here we identify gene expression outliers, or individuals showing extreme expression levels for a particular gene, across 44 human tissues by using combined analyses of whole genomes and multi-tissue RNA-sequencing data from the Genotype-Tissue Expression (GTEx) project v6p release. We find that 58% of underexpression and 28% of overexpression outliers have nearby conserved rare variants compared to 8% of non-outliers. Additionally, we developed RIVER (RNA-informed variant effect on regulation), a Bayesian statistical model that incorporates expression data to predict a regulatory effect for rare variants with higher accuracy than models using genomic annotations alone. Overall, we demonstrate that rare variants contribute to large gene expression changes across tissues and provide an integrative method for interpretation of rare variants in individual genomes.